40.14
+0.09(+0.22%)
Currency In USD
| Previous Close | 40.05 |
| Open | 40 |
| Day High | 40.56 |
| Day Low | 39.71 |
| 52-Week High | 46.01 |
| 52-Week Low | 14.8 |
| Volume | 334,499 |
| Average Volume | 917,696 |
| Market Cap | 3.01B |
| PE | -19.58 |
| EPS | -2.05 |
| Moving Average 50 Days | 41.55 |
| Moving Average 200 Days | 31.1 |
| Change | 0.09 |
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCApplications for the fellowship are due on February 27, 2026 SCHAUMBURG, Ill. and IRVINE, Calif.,
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
GlobeNewswire Inc.
Dec 05, 2025 1:30 PM GMT
Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort PCORE-008 Cohort A Data in HR BCG-Naïve NMIBC demonstrates 88% CR and favorable safety with optimized admi
CG Oncology Announces New Board Member and Board Transition
GlobeNewswire Inc.
Nov 26, 2025 12:00 PM GMT
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing an